N/A
N=108
Effectiveness of Anti-IL-5/IL5R Inhibitors
Severe Asthma
Bottom Line
View on ClinicalTrials.gov: NCT06239441 ↗Enrolled (actual)
108
Serious AEs
—
Results posted
Oct 2024
Primary outcome: Primary: Response to IL5/IL5R Antagonist — 76.5; 82.5 Percent
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- IL5/IL5R Antagonists (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response to IL5/IL5R Antagonist |
76.5; 82.5 | — |
| PRIMARY Remission Rate With IL5/IL5R Antagonist |
45; 24.4 | — |
Summary
The goal of this observational study is to assess the response to treatment, in patients 18 years and older diagnosed with severe asthma in whom an IL5/IL5R antagonists was initiated between 2012 and 2020.
The main question[s] it aims to answer are:
* What is the response rate after one year of treatment with IL5/IL5R antagonists.
* What is the response and remission rate after one year of treatment with IL5/IL5R antagonists in subjects who fullfilled the original randomized control trials (RCTs) inclusion criteria compared with those who did not.
Eligibility Criteria
Inclusion Criteria
All patients 18 years and older diagnosed with severe asthma in whom an IL5/IL5R antagonist was initiated at the outpatient asthma clinic of a tertiary center (Sacre-Coeur Hospital) in Montreal.c between 2012 and 2020.
Exclusion Criteria
None
Data sourced from ClinicalTrials.gov (NCT06239441). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.